• Combination of ISS and the EMC92 gene expression classifier is a novel clinically applicable risk classification for survival in multiple myeloma.
Introduction
In multiple myeloma (MM) patients, malignant plasma cells accumulate in the bone marrow, leading to a wide range of clinical symptoms which include bone disease, hypercalcemia, renal impairment and anemia. 1 The prognosis is variable, with survival for newly diagnosed patients ranging from less than two to more than twenty years. 2 Adequate prognostication of disease outcome is important in order to make treatment choices and to allocate high-risk patients to alternative treatment options. Clinical trials that address specific treatment of highrisk patients include TT4, TT5 and MUK9 (TT4: Total Therapy 4, NCT00734877; TT5: Total Therapy 5, NCT02128230; MUK9, OPTIMUM trial, Myeloma UK Clinical Trial Network).
Heterogeneous treatment outcome can in part be explained by different biological subgroups in MM, which are characterized by primary translocations involving genes such as MMSET (t(4;14)), and c-MAF (t(14;16)). 3, 4 These subgroups can be identified using gene expression profiling. 5, 6 In addition, gene expression profiling has been utilized to establish classifiers for prognostication. The EMC92 is a robust risk marker for the identification of high-risk MM, and was validated in independent clinical trials showing a solid and independent performance in comparison to other MM GEP classifiers such as UAMS70. [7] [8] [9] [10] [11] [12] [13] Clinical prognostic systems for MM, are primarily based on beta 2 -microglobulin (β 2 M), albumin, lactate dehydrogenase, Creactive protein, calcium and creatinine. 14, 15 The International Staging System (ISS) is based on β 2 M and albumin, with stage I representing limited disease, stage II intermediate and stage
III the most unfavorable disease. 16 Today it is used as the standard clinical risk classification for MM.
FISH based cytogenetics and gene expression profiling are biology based prognostic markers. 17 ISS was combined with high-risk cytogenetic markers t(4;14) and deletion of 17p (del17p) to establish novel prognostic risk classifications as proposed by Neben 18 and AvetLoiseau 19 . Recently, serum lactate dehydrogenase (LDH) was added as a component to this marker combination. 20 Other prognostic systems include combinations of cytogenetic markers, such as the combination of del17p, translocation t(4;14) and gain of 1q (gain1q).
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The goal of this study was to evaluate all published risk markers used in MM and to compare combinations of FISH, ISS and GEP based prognostic systems. By applying a study design with independent discovery and validation sets, we demonstrated that ISS can be combined with gene expression signatures into powerful classifiers for MM.
Methods

Clinical data
The clinical data from the HOVON-65/GMMG-HD4 (HO65/HD4), MRC-IX, UAMS-TT2, UAMS-TT3, IFM-G (all newly diagnosed patients) and APEX (relapse patients) trials were used. [7] [8] [9] 19, 22, 23 The IFM-G cohort is a clinical database of patients not separately published and was included in the ISS development. 16 Treatment regimens of the trials from which these datasets were derived are summarized in Table 1 . Overall survival (OS) or progressionfree survival (PFS) and at least one prognostic marker were available for all patients (Table 1 ; Figure S1 ). All patients signed an informed consent in accordance with the Declaration of Helsinki and all protocols were approved by institutional review boards.
Gene expression profiling (GEP)
All GEP data are Affymetrix HG U133 Plus 2.0 platform based, except for the APEX study (Affymetrix U133 A/B platform). HO65/HD4 GEP was performed in our lab as described previously (n=327; GSE19784). 6, 7, 21 Other GEP sets were: TT2 (n=345; GSE24080) 8 , TT3
(n=238; E-TABM-1138 and GSE24080) 24 , MRC-IX (n=247; GSE15695) 22 and APEX (n=264; GSE9782) 23 . Due to unavailable survival data, the HM dataset (n=206; E-MTAB-362), was used only to determine the probe set means and variances for the training set of the HM19
classifier.
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Standard prognostic markers Availability of risk markers and patients per dataset is shown in Table 1 and Figure S1 . The
International staging system (ISS) was determined by combining serum levels of β 2 M and albumin. 16 Cytogenetics by Fluorescence in situ hybridization (FISH) was used with a 10% cut-off level except for a 20% cut-off used for numerical abnormalities in the MRC-IX trial. 19, [25] [26] [27] Gain of chromosome 9 (gain9), one of the hyperdiploid chromosomes and most frequently available marker for this purpose, was used as a proxy for hyperdiploidy. 28 FISH probes used in MRC-IX and HO65/HD4 were described before. 25, 29 , GPI50 11 (both three risk group classifiers). Normalization and cut-offs were calculated as described previously (see supplemental methods for a brief description).
Statistical analyses
In Figure 1 , a flowchart of the analyses is given. The association of risk markers with survival was assessed using a Cox survival model (R 'survival' package, version 2.38-1). [30] [31] [32] To account for heterogeneous survival between studies, models were stratified per trial cohort. Figure S2B and extensively described in the supplemental methods. Briefly, since missing data may confound the analyses, combinations with increased risk for confounding were excluded (Table S1 ; supplemental methods). Subsequently, the data were randomly split into a discovery and validation set. The discovery set was used for finding meaningful combinations of markers as well as the most optimal way to split patients into subgroups, using these combinations. Stringent validation was performed in the designated validation set to confirm their prognostic strength. Finally, all new combinations and existing markers were ranked, with a low rank score indicating a high performing risk marker.
Results
Confirmation of existing risk markers
The value of 20 existing risk markers was evaluated in a data set of 4750 patients. The markers and used cohorts are given in Table 1 . The prognostic value was evaluated correcting for the differences in survival between cohorts ( Figure 2 ; Figures S3-5; Table S2 ).
For all markers at least 2 cohorts were available. All gene expression (GEP) classifiers demonstrated a highly significant performance for OS. Hazard ratios for GEP classifiers ranged from 2.0 (95%CI = 1. classifiers: 18% (EMC92), 12% (UAMS17), 10% (GPI50), 9% (UAMS70), 8% (UAMS80 and HM19; Table 1 ).
FISH markers with prognostic strength can be distinguished from markers with no or disputable value. For OS, markers t(4;14), del17p, gain1q and del13q performed well with hazard ratios ranging between 1.7 (95%CI: 1.5 -1.8; del13q) up to 2.3 (2.0 -2.6; del17p). The markers gain9, t(11;14), t(14;16) and t(14;20) were clearly not significant or had high variance due to lack of predictive value or small number of positive cases. These markers were excluded from further analyses. A similar pattern was found for PFS, but the strength of the markers was generally lower with PFS hazard ratios ranging from 1.4 (95%CI: 1.3 -1.5; del13q) up to 1.8 (1.6 -2.0; t(4;14)).
ISS was confirmed as a valuable and highly significant prognostic marker. A hazard ratio of To correct for heterogeneity between studies, all analyses were corrected for the survival differences between trials as a result of differences in treatment, disease stage and patient populations. To evaluate the effect of this correction, all analyses were repeated per cohort and highly similar results were obtained, suggesting that these risk markers perform similarly across different cohorts (supplemental results).
Pair-wise combinations of risk markers
The next analysis was performed to explore combinations of risk markers. As indicated above, 16 of 20 evaluated markers had significant associations with OS and/or PFS. Based on these 16, all possible pair-wise combinations were generated. 20 combinations were significant in the discovery set of which 16 remained significant in the independent validation set ( Figure 2 and Figure S8A -B; Table S3 ). In 10 of 16 combinations, ISS was combined with either GEP classifiers (n=5) or FISH markers (n=5), illustrating the strong additive power of ISS to these markers. Combinations of GEP (n=3) and FISH markers were observed (n=3), but no combinations of FISH with GEP. Two combinations divided patients in 3 groups, ten in 4 groups and four into 5 groups. Figure S10 ).
The composition of the four groups in terms of ISS, EMC92 and FISH markers is shown in Table 3 . Interestingly, within the EMC92-ISS lowest-risk group, 75% of patients -with truly favorable prognosis (Table S4) 
Discussion
Important prognostic markers in MM are based on ISS, FISH markers and GEP classifiers.
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13,16,17 Previously, we showed that combining various GEP classifiers resulted in a stronger prediction of the high-risk population. 7 Here we systematically evaluated additional, new combinations of prognostic markers. We limited the search for new compound risk markers to pair-wise combinations of existing markers. This choice is mainly driven by the lack of complete data sets which contain all risk markers (as shown in Figure S1 ), which hinders the analyses of more complex risk-models The number of patients positive for specific markers was remarkably stable between cohorts, irrespective of the type of marker. This adds strength to the belief that these markers, and thus decisions based on them can be reliably replicated.
Three findings are of particular interest: first, ISS has a clear and independent value in combination with either GEP classifiers or FISH markers. GEP classifiers combined with ISS are the strongest risk classifications found here. By combining the EMC92 gene classifier with ISS, patients are effectively stratified into four risk groups including a distinctive low-risk group of 38% and a high-risk group of 17%. This strong additive strength of ISS to GEP has been recognized before in a previous smaller study. 34 Also ISS was integrated with GEP and other factors, but this risk-score did not take into account correlations between markers, and was generated without using a solid discovery/validation design. 35 In contrast, we have opted for a study design in which part of the data was reserved for validation. 19 Incorporating LDH and bone imaging was outside the scope of this study because these markers were not consistently available. 20 Combining GEP with ISS may become an attractive option for prognostication. The EMC92-ISS classification is independent from therapy choice: the EMC92 was shown to function in bortezomib clinical trials as well as in thalidomide and more conventional regimens. 7 In contrast, bortezomib and other novel agents may abrogate the unfavourable impact of some FISH markers on PFS. 29 EMC92-ISS is useful since it can identify both high-risk and low-risk MM. This is an advantage over FISH markers which only seem to identify high risk patients.
Moreover, the technical applicability of GEP and its costs are thought to be comparable to FISH.
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The agreement between GEP classifiers in terms of pathways is of interest. Although the primary force for classifier discovery is association with survival, the genes within classifiers appear to converge on the cell cycle pathways. Indeed, proliferative capacity, assessed as the plasma cell labeling index or by Ki-67 staining, has long been recognized to be an important prognostic factor.
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The clinical applicability of stratification into four risk groups will be increasingly relevant in the era of novel treatment modalities being available. First, increased accuracy of prognosis can improve patient counseling. 17 Secondly, and more important, risk-stratification may lead to adaptation of treatment according to risk status. This composite risk marker opens the way to better risk-stratification in clinical trials and explore novel drugs in different risk groups.
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This could effectively be a first step towards a more individual treatment, using patient specific markers as a directional key.
Based on the current study we conclude that the combination of EMC92 with ISS is a strong disease based prognosticator for survival in MM. This risk classification is a good candidate to stratify patients for treatment options in a clinical trial. Table 3 . Distribution of markers in each of the four EMC92-ISS based risk groups. Shown are the numbers in the data for which the EMC92-ISS risk classification could be determined. n, number of patients in the EMC92-ISS based risk group for which the specified marker was available. Positive, the percentage of patients positive for the specified marker; HR, the percentage of patients indicated as 1 -12) ). In the right panel, a plus sign indicates whether a data set could be used for the analysis of a specific marker or combination (for details of available data, see Table 1 and Figure S1 ). For the EMC92-ISS combination, the following datasets could be used: APEX, MRC-IX, TT2 and TT3. 
